Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Azole resistance in Candida.

Literature DB >> 9177959

Azole resistance in Candida.

Abstract

Resistance of Candida to azoles is an increasing problem. Susceptibility testing of Candida against fluconazole and ketoconazole is now feasible and desirable. Good correlation of resistance in vitro with clinical failure of fluconazole therapy has now been shown in mucosal candidiasis. The relationship, if any, between resistance and clinical failure in the context of invasive candidiasis is not clear at present and additional correlative work needs to be done. Monitoring of resistance trends in Candida is clearly important now.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1997 PMID： 9177959 DOI： 10.1007/BF01695630

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

154 in total

1. Standardized susceptibility testing of fluconazole: an international collaborative study.

Authors: M A Pfaller; B Dupont; G S Kobayashi; J Müller; M G Rinaldi; A Espinel-Ingroff; S Shadomy; P F Troke; T J Walsh; D W Warnock
Journal: Antimicrob Agents Chemother Date: 1992-09 Impact factor: 5.191

2. Increased gastric pH and the bioavailability of fluconazole and ketoconazole.

Authors: R A Blum; D T D'Andrea; B M Florentino; J H Wilton; D M Hilligoss; M J Gardner; E B Henry; H Goldstein; J J Schentag
Journal: Ann Intern Med Date: 1991-05-01 Impact factor: 25.391

3. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.

Authors: M A Fisher; S H Shen; J Haddad; W F Tarry
Journal: Antimicrob Agents Chemother Date: 1989-09 Impact factor: 5.191

4. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.

Authors: J A Barone; J G Koh; R H Bierman; J L Colaizzi; K A Swanson; M C Gaffar; B L Moskovitz; W Mechlinski; V Van de Velde
Journal: Antimicrob Agents Chemother Date: 1993-04 Impact factor: 5.191

Review 5. Molecular mechanisms of drug resistance in fungi.

Authors: H Vanden Bossche; P Marichal; F C Odds
Journal: Trends Microbiol Date: 1994-10 Impact factor: 17.079

6. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors: M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal: Am J Med Date: 1996-06 Impact factor: 4.965

7. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors: C Beck-Sagué; W R Jarvis
Journal: J Infect Dis Date: 1993-05 Impact factor: 5.226

8. Altered P450 activity associated with direct selection for fungal azole resistance.

Authors: T Joseph-Horne; D Hollomon; R S Loeffler; S L Kelly
Journal: FEBS Lett Date: 1995-10-30 Impact factor: 4.124

9. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.

Authors: J R Maenza; J C Keruly; R D Moore; R E Chaisson; W G Merz; J E Gallant
Journal: J Infect Dis Date: 1996-01 Impact factor: 5.226

10. [In vitro evaluation of the sensitivity to fluconazole of different species of yeasts isolated in pathology].

Authors: P Regli; A Blancard; M Goudard; J Moulin-Traffort; J M Sarzier; M Quilici
Journal: Pathol Biol (Paris) Date: 1992-05

17 in total

Review 1. Fungal resistance.

Authors: H Bernhardt; K Zimmermann; M Knoke
Journal: Infection Date: 1999 Impact factor: 3.553

2. Multicenter evaluation of the new VITEK 2 advanced colorimetric yeast identification card.

Authors: D Jane Hata; Leslie Hall; Annette W Fothergill; Davise H Larone; Nancy L Wengenack
Journal: J Clin Microbiol Date: 2007-01-31 Impact factor: 5.948

3. Evaluation of the fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility.

Authors: F Witthuhn; D Toubas; I Béguinot; D Aubert; C Rouger; G Remy; J M Pinon
Journal: J Clin Microbiol Date: 1999-03 Impact factor: 5.948

4. When should Candida isolates be tested for susceptibility to azole antifungal agents?

Authors: J Bille
Journal: Eur J Clin Microbiol Infect Dis Date: 1997-04 Impact factor: 3.267

5. Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates.

Authors: P Marichal; J Gorrens; L Laurijssens; K Vermuyten; C Van Hove; L Le Jeune; P Verhasselt; D Sanglard; M Borgers; F C Ramaekers; F Odds; H Vanden Bossche
Journal: Antimicrob Agents Chemother Date: 1999-11 Impact factor: 5.191

6. Evaluation of the VITEK 2 system for rapid identification of yeasts and yeast-like organisms.

Authors: B Graf; T Adam; E Zill; U B Göbel
Journal: J Clin Microbiol Date: 2000-05 Impact factor: 5.948

7. Vaginal yeasts in the era of "over the counter" antifungals.

Authors: P P Walker; M T Reynolds; H R Ashbee; C Brown; E G Evans
Journal: Sex Transm Infect Date: 2000-12 Impact factor: 3.519

8. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.

Authors: O Marchetti; P Moreillon; M P Glauser; J Bille; D Sanglard
Journal: Antimicrob Agents Chemother Date: 2000-09 Impact factor: 5.191

9. In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.

Authors: Lingmei Sun; Shujuan Sun; Aixia Cheng; Xiuzhen Wu; Yu Zhang; Hongxiang Lou
Journal: Antimicrob Agents Chemother Date: 2009-01-26 Impact factor: 5.191

10. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect.

Authors: Daisuke Kobayashi; Kei Kondo; Nobuyuki Uehara; Seiko Otokozawa; Naoki Tsuji; Atsuhito Yagihashi; Naoki Watanabe
Journal: Antimicrob Agents Chemother Date: 2002-10 Impact factor: 5.191